MedTrace Logo

PET/MR in Post Stroke Cardiac Inflammation Study

NCT05791617 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 12

Last updated 2024-03-13

No results posted yet for this study

Summary

Patients with stroke have a 25x higher risk of cardiovascular complications within the first 30 days of the event compared to individuals without stroke. The mechanisms behind these complications are not well understood. Evidence suggests that inflammation plays a central role. With the present proof-of-concept prospective cohort study, the investigators aim to demonstrate that patients develop cardiac inflammation after stroke by performing positron emission tomography (PET) magnetic resonance imaging (MRI) of the heart within 15 days after stroke. As a secondary aim, the investigators will evaluate whether post-stroke cardiac inflammation persists at 3 months after stroke. The control group will be comprised of age- and sex-matched individuals without stroke.

Conditions

Interventions

DIAGNOSTIC_TEST

cardiac PET/MRI

Patients will undergo cardiac PET/MRI scanning at 30±5 days and at 90±5 days post-stroke.

DIAGNOSTIC_TEST

Inflammatory markers

Measurement of a panel of 92 systemic inflammatory markers on patients' blood samples at 30±5 days and at 90±5 days post-stroke

DIAGNOSTIC_TEST

Diagnostic Test: NT-proBNP

NT-proBNP is useful both in the diagnosis and prognosis of heart failure and is considered to be a gold standard biomarker in heart failure. Measurement of NT-proBNP on patients' blood samples at 30±5 days and at 90±5 days post-stroke

Sponsors & Collaborators

  • London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's

    lead OTHER

Principal Investigators

  • Luciano Sposato, MD · London Health Sciences Center, Western University

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-07-01
Primary Completion
2024-09-02
Completion
2025-09-02

Countries

  • Canada

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05791617 on ClinicalTrials.gov